
US Targets Germany with Pharma Price Investigation
The US investigates Germany under Section 301 of the Trade Act of 1974, alleging its drug price regulation system forces US patients and businesses to pay disproportionately higher prices for pharmaceutical R&D, potentially leading to new tariffs.


















